GlassScriptPhysician profile
Jamie Green
NPI 1033658828
$1,882.44
in general payments reported to CMS, 2019-2025
13 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.80 · 2022: $32.72 · 2023: $475 · 2024: $236 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $464.97 | 2024-2025 | General - Pain Management, Intracept, Watchman |
| Medtronic, INC. | $268.12 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.85 | 2022-2025 | Relistor, Xifaxan, Trulance |
| Abbott Laboratories | $199.86 | 2023-2025 | Octrode, Proclaim, Eterna |
| Mml US, INC. | $197.49 | 2023-2025 | Reactiv8 |
| Nevro Corp. | $184.98 | 2023 | Senza |
| Vertos Medical, INC. | $147.85 | 2023 | Mild Device Kit |
| Curonix LLC | $76.42 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| International Rehabilitative Sciences, INC | $31.36 | 2024 | Rs 4i Plus Sequential Stimulator |
| Amgen INC. | $23.80 | 2021 | |
| Biogen, INC. | $18.17 | 2022 | |
| Foundation Fusion Solutions, LLC | $17.11 | 2024 | |
| Saluda Medical Americas, INC. | $15.46 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.